Article
Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 1 Feb 2015
Boglione L, De Nicolò A, Cardellino C S, Ruggiero T, Ghisetti V, Cariti G, Di Perri G, D'Avolio A
Abstract excerpt
In a prospective cohort of 18 patients treated with boceprevir, we examined the role of boceprevir plasma concentration at the onset of breakthrough during the treatment. Nine patients experienced breakthrough during therapy. The resistance patterns were as follows: S122S/R, I132V, T54A/I132V, V156S/I170A, V36M/T54S/R155K, V36M/R155K and T54/R155K. Boceprevir-S isomer (SCH 534128) median concentration in patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.